|
|
 |
|
Viewing report
|
|
|
|
Arthritis Therapeutics Market to 2016 - Biologics Revolutionize Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
GBI Research, Oct 2010, Pages: 125
“Arthritis Therapeutics Market to 2016 - Biologics Revolutionize Treatment of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global hepatitis therapeutics market.. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
Scope
The scope of this report includes:
- Annualized market data for the arthritis therapeutics market from 2001 to 2009, forecast forward to 2016.
- Market characterization of the arthritis therapeutics market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development. .
- Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global arthritis therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis
Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
Bone and Joint Infection Market to 2016 - Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment
Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs
Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin
Anticonvulsants Market to 2016 - Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies
The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets
Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market
Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets
Specialty Pharmaceutical Industry - 2011 Yearbook
|
|
|
|
